The right test for the right patients
QHerit™ helps you and your patients understand their genetic risks so that together, you can make informed decisions. It’s built on industry-leading NGS and a robust and growing genomics database that tests for disorders recommended by ACOG, ACMG, and Jewish advocacy groups for carrier screening.
This includes testing for spinal muscular atrophy, cystic fibrosis, and other disorders that can play an important role in your patients’ healthcare and family planning. QHerit focuses on disorders that:
- Have potentially devastating consequences
- Result in early death
- Create a need for significant early intervention
QHerit provides a clear picture, testing only clinically relevant variants within genes.
| ||
| Beta-Hemoglobinopathies |
| Bloom Syndrome |
| Canavan Disease |
| Cystic Fibrosis (CF) |
| Dihydrolipoamide Dehydrogenase Deficiency (DLD Deficiency) |
| Familial Dysautonomia |
| Familial Hyperinsulinism |
| Fanconi Anemia Type C |
| Fragile X Syndrome |
| ||
| Glycogen Storage Disease Type Ia |
| Joubert Syndrome 2 |
| Maple Syrup Urine Disease |
| Mucolipidosis Type IV |
| Nemaline Myopathy |
| Niemann-Pick Disease, Types A & B |
| Spinal Muscular Atrophy (SMA) |
| Tay-Sachs Disease |
| Usher Syndrome, Type 1F |
| Usher Syndrome, Type IIIA |
| Walker-Warburg Syndrome |
See brief descriptions of each condition here.
Please visit QHerit.com/ClinicalInfo for additional clinical information and references.